Experience
InnoPharma Licensing, Inc.; Lupin Ltd.; and Metrics, Inc.
Bausch Health Companies
Represented patent owner in a series of inter partes review challenges to an aqueous formulation of bromfenac with tyloxapol. Successfully secured non-institution of several proceedings and claims, and in several cases that proceeded to final written decision, persuaded the Board to confirm some or all of the challenged claims.
InnoPharma Licensing, Inc.; Lupin Ltd.; and Metrics, Inc. v. Bausch Health Companies, IPR2015-00902, -00903, -01097, -01099, -01105, -01871, -01100, IPR2014-01041, -01043, PTAB, Judges Franklin, Obermann, Prats
Mylan Pharmaceuticals Inc. v. Senju Pharmaceutical Co., Ltd.
Senju Pharmaceutical Co., Ltd.; Bausch & Lomb Incorporated
Hartig Drug Co. Inc. v. Senju Pharmaceutical Co. Ltd.
Senju Pharmaceuticals Co. Ltd.
Senju Pharmaceutical Co., Ltd. v. Apotex Inc.
Senju Pharmaceutical Co., Ltd.; Bausch + Lomb Inc.
Senju Pharmaceutical Co.; Bausch + Lomb v. Lupin Ltd.
Senju Pharmaceutical Co.; Bausch + Lomb
Housey Pharmaceuticals, Inc. v. Otsuka Pharmaceutical Co. Ltd.
Otsuka Pharmaceutical Co. Ltd.
Otsuka Pharmaceutical Co., Ltd. v. Teva Pharmaceuticals USA, Inc.
Otsuka Pharmaceutical Co.
Lupin Pharmaceuticals, Inc. v. Pozen Inc.
Horizon Pharma USA, Inc.; Pozen Inc.
Apotex Inc. v. Senju Pharmaceutical
Senju Pharmaceuticals Co. Ltd.
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.